Loading...
•
Oct 31, 2021
Cooper Q4 2021 Earnings Report
CooperCompanies reported an increase in revenue and earnings for the fourth quarter of 2021.
Key Takeaways
CooperCompanies announced strong Q4 and full-year 2021 results, with Q4 revenue up 11% year-over-year to $759.1 million and GAAP EPS up 35% to $2.21. The company achieved record annual revenue, profits, and cash flow, driven by market share gains in contact lenses and fertility.
Fourth quarter revenue increased 11% year-over-year to $759.1 million.
Fourth quarter GAAP diluted earnings per share (EPS) $2.21, up 35% from last year's fourth quarter.
Fourth quarter Non-GAAP diluted EPS $3.28, up 4% from last year's fourth quarter.
Gross margin 66% compared with 62% in last year’s fourth quarter.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Office & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
CooperCompanies provided fiscal year 2022 guidance, with total revenue expected to be between $3,032 and $3,090 million and non-GAAP diluted earnings per share between $13.60 and $14.00. This guidance does not include the Generate Life Sciences acquisition.
Positive Outlook
- Fiscal 2022 total revenue $3,032 - $3,090 million (up 6% to 8% in constant currency)
- CVI revenue $2,225 - $2,267 million (up 6% to 8% in constant currency)
- CSI revenue $807 - $823 million (up 6% to 8% in constant currency)
- Fiscal 2022 non-GAAP diluted earnings per share $13.60 - $14.00 (up 9.5% to 12.5% in constant currency)
- Company is well positioned to continue executing on our growth strategies across both businesses
Challenges Ahead
- Our fiscal year 2022 guidance does not include the Generate Life Sciences acquisition announced on November 10th, 2021.
- Excludes amortization and impairment of intangible assets, and other exceptional or unusual income or gains and charges or expenses including acquisition, integration and manufacturing related costs which we may incur as part of our continuing operations.
- The company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses.
- Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance.
- Resurgences as a significant risk factor to our outlook
Revenue & Expenses
Visualization of income flow from segment revenue to net income